{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T08:42:07Z","timestamp":1742978527205,"version":"3.40.3"},"publisher-location":"Berlin, Heidelberg","reference-count":232,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783642307256"},{"type":"electronic","value":"9783642307263"}],"license":[{"start":{"date-parts":[[2012,9,5]],"date-time":"2012-09-05T00:00:00Z","timestamp":1346803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,9,5]],"date-time":"2012-09-05T00:00:00Z","timestamp":1346803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/978-3-642-30726-3_24","type":"book-chapter","created":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T11:24:11Z","timestamp":1349090651000},"page":"543-587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacology and Clinical Use of Sex Steroid Hormone Receptor Modulators"],"prefix":"10.1007","author":[{"given":"A.","family":"Cleve","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.-H.","family":"Fritzemeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Haendler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Schwede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Wintermantel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,5]]},"reference":[{"key":"24_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jsbmb.2008.11.015","volume":"113","author":"W Afhuppe","year":"2009","unstructured":"Afhuppe W, Sommer A, Muller J, Schwede W, Fuhrmann U, Moller C (2009) Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system. J Steroid Biochem Mol Biol 113:105\u2013115","journal-title":"J Steroid Biochem Mol Biol"},{"key":"24_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jsbmb.2009.12.011","volume":"119","author":"W Afhuppe","year":"2010","unstructured":"Afhuppe W, Beekman JM, Otto C, Korr D, Hoffmann J, Fuhrmann U, Moller C (2010) In vitro characterization of ZK 230211\u2013A type III progesterone receptor antagonist with enhanced antiproliferative properties. J Steroid Biochem Mol Biol 119:45\u201355","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"Suppl 1","key":"24_CR3","first-page":"77","volume":"12","author":"H Akaza","year":"2005","unstructured":"Akaza H (2005) Effectiveness of maximal androgen blockade (MAB): illusion or reality? Can J Urol 12(Suppl 1):77\u201380","journal-title":"Can J Urol"},{"key":"24_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1349-7006.2010.01774.x","volume":"102","author":"H Akaza","year":"2011","unstructured":"Akaza H (2011) Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness. Cancer Sci 102:51\u201356","journal-title":"Cancer Sci"},{"key":"24_CR5","first-page":"33","volume":"62","author":"PG Artini","year":"2010","unstructured":"Artini PG, Di Berardino OM, Simi G, Papini F, Ruggiero M, Monteleone P, Cela V (2010) Best methods for identification and treatment of PCOS. Minerva Ginecol 62:33\u201348","journal-title":"Minerva Ginecol"},{"key":"24_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.mam.2006.07.001","volume":"27","author":"P Ascenzi","year":"2006","unstructured":"Ascenzi P, Bocedi A, Marino M (2006) Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med 27:299\u2013402","journal-title":"Mol Aspects Med"},{"key":"24_CR7","doi-asserted-by":"publisher","first-page":"6522","DOI":"10.1158\/0008-5472.CAN-09-1111","volume":"69","author":"RM Attar","year":"2009","unstructured":"Attar RM, Jure-Kunkel M, Balog A, Cvijic ME, Dell-John J, Rizzo CA, Schweizer L, Spires TE, Platero JS, Obermeier M et al (2009a) Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer. Cancer Res 69:6522\u20136530","journal-title":"Cancer Res"},{"key":"24_CR8","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1158\/1078-0432.CCR-08-1171","volume":"15","author":"RM Attar","year":"2009","unstructured":"Attar RM, Takimoto CH, Gottardis MM (2009b) Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 15:3251\u20133255","journal-title":"Clin Cancer Res"},{"key":"24_CR9","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1038\/emboj.2011.340","volume":"30","author":"MA Augello","year":"2011","unstructured":"Augello MA, Hickey TE, Knudsen KE (2011) FOXA1: master of steroid receptor function in cancer. EMBO J 30:3885\u20133894","journal-title":"EMBO J"},{"key":"24_CR10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0015-0282(16)54527-0","volume":"56","author":"OM Avrech","year":"1991","unstructured":"Avrech OM, Golan A, Weinraub Z, Bukovsky I, Caspi E (1991) Mifepristone (RU486) alone or in combination with a prostaglandin analogue for termination of early pregnancy: a review. Fertil Steril 56:385\u2013393","journal-title":"Fertil Steril"},{"key":"24_CR11","doi-asserted-by":"publisher","first-page":"23825","DOI":"10.1074\/jbc.M102611200","volume":"276","author":"DL Bain","year":"2001","unstructured":"Bain DL, Franden MA, McManaman JL, Takimoto GS, Horwitz KB (2001) The N-terminal region of human progesterone B-receptors: biophysical and biochemical comparison to A-receptors. J Biol Chem 276:23825\u201323831","journal-title":"J Biol Chem"},{"key":"24_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.reprotox.2005.01.002","volume":"20","author":"DD Baird","year":"2005","unstructured":"Baird DD, Newbold R (2005) Prenatal diethylstilbestrol (DES) exposure is associated with uterine leiomyoma development. Reprod Toxicol 20:81\u201384","journal-title":"Reprod Toxicol"},{"key":"24_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.contraception.2006.06.004","volume":"74","author":"JL Bapst","year":"2006","unstructured":"Bapst JL, Ermer JC, Ferron GM, Foss D, Orczyk GP (2006) Pharmacokinetics and safety of tanaproget, a nonsteroidal progesterone receptor agonist, in healthy women. Contraception 74:414\u2013418","journal-title":"Contraception"},{"key":"24_CR14","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1517\/14656566.7.13.1685","volume":"7","author":"S Barmoshe","year":"2006","unstructured":"Barmoshe S, Zlotta AR (2006) Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments. Expert Opin Pharmacother 7:1685\u20131699","journal-title":"Expert Opin Pharmacother"},{"key":"24_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2165\/00002512-199405010-00006","volume":"5","author":"LB Barradell","year":"1994","unstructured":"Barradell LB, Faulds D (1994) Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer. Drugs Aging 5:59\u201380","journal-title":"Drugs Aging"},{"key":"24_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.mcna.2011.03.001","volume":"95","author":"N Bassil","year":"2011","unstructured":"Bassil N (2011) Late-onset hypogonadism. Med Clin North Am 95:507\u2013523x","journal-title":"Med Clin North Am"},{"key":"24_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cger.2010.02.003","volume":"26","author":"N Bassil","year":"2010","unstructured":"Bassil N, Morley JE (2010) Late-life onset hypogonadism: a review. Clin Geriatr Med 26:197\u2013222","journal-title":"Clin Geriatr Med"},{"key":"24_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF00931228","volume":"241","author":"EE Baulieu","year":"1987","unstructured":"Baulieu EE, Ulmann A, Philibert D (1987) Contragestion by antiprogestin RU 486: a review. Arch Gynecol Obstet 241:73\u201385","journal-title":"Arch Gynecol Obstet"},{"key":"24_CR19","first-page":"517","volume":"61","author":"CK Baumann","year":"2009","unstructured":"Baumann CK, Castiglione-Gertsch M (2009) Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer. Minerva Ginecol 61:517\u2013539","journal-title":"Minerva Ginecol"},{"key":"24_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/SPC.0b013e32830c48a3","volume":"2","author":"EK Beardsley","year":"2008","unstructured":"Beardsley EK, Chi KN (2008) Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer. Curr Opin Support Palliat Care 2:161\u2013166","journal-title":"Curr Opin Support Palliat Care"},{"key":"24_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1749-6632.1996.tb16231.x","volume":"784","author":"M Beato","year":"1996","unstructured":"Beato M, Truss M, Chavez S (1996) Control of transcription by steroid hormones. Ann N Y Acad Sci 784:93\u2013123","journal-title":"Ann N Y Acad Sci"},{"key":"24_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1586\/17434440.5.5.639","volume":"5","author":"G Benagiano","year":"2008","unstructured":"Benagiano G, Gabelnick H, Farris M (2008a) Contraceptive devices: intravaginal and intrauterine delivery systems. Expert Rev Med Devices 5:639\u2013654","journal-title":"Expert Rev Med Devices"},{"key":"24_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1586\/17434440.5.5.623","volume":"5","author":"G Benagiano","year":"2008","unstructured":"Benagiano G, Gabelnick H, Farris M (2008b) Contraceptive devices: subcutaneous delivery systems. Expert Rev Med Devices 5:623\u2013637","journal-title":"Expert Rev Med Devices"},{"key":"24_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/humu.20848","volume":"30","author":"JP Bergerat","year":"2009","unstructured":"Bergerat JP, Ceraline J (2009) Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Hum Mutat 30:145\u2013157","journal-title":"Hum Mutat"},{"key":"24_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/MCO.0b013e32832a3d79","volume":"12","author":"S Bhasin","year":"2009","unstructured":"Bhasin S, Jasuja R (2009) Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care 12:232\u2013240","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"24_CR26","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1210\/jc.2009-2354","volume":"95","author":"S Bhasin","year":"2010","unstructured":"Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95:2536\u20132559","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 3","key":"24_CR27","doi-asserted-by":"publisher","first-page":"S189","DOI":"10.1016\/S0959-8049(11)70164-2","volume":"47","author":"D Bianchini","year":"2011","unstructured":"Bianchini D, de Bono JS (2011) Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer. Eur J Cancer 47(Suppl 3):S189\u2013194","journal-title":"Eur J Cancer"},{"key":"24_CR28","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.contraception.2011.02.013","volume":"84","author":"J Bitzer","year":"2011","unstructured":"Bitzer J, Simon JA (2011) Current issues and available options in combined hormonal contraception. Contraception 84:342\u2013356","journal-title":"Contraception"},{"key":"24_CR29","doi-asserted-by":"publisher","first-page":"6201","DOI":"10.1073\/pnas.0500381102","volume":"102","author":"CE Bohl","year":"2005","unstructured":"Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT (2005) Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 102:6201\u20136206","journal-title":"Proc Natl Acad Sci USA"},{"key":"24_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0079-6123(08)81012-6","volume":"181","author":"WC Boon","year":"2010","unstructured":"Boon WC, Chow JD, Simpson ER (2010) The multiple roles of estrogens and the enzyme aromatase. Prog Brain Res 181:209\u2013232","journal-title":"Prog Brain Res"},{"key":"24_CR31","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.fertnstert.2011.08.021","volume":"96","author":"P Bouchard","year":"2011","unstructured":"Bouchard P, Chabbert-Buffet N, Fauser BC (2011) Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril 96:1175\u20131189","journal-title":"Fertil Steril"},{"key":"24_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-61779-243-4_1","volume":"776","author":"AO Brinkmann","year":"2011","unstructured":"Brinkmann AO (2011) Molecular mechanisms of androgen action\u2013a historical perspective. Methods Mol Biol 776:3\u201324","journal-title":"Methods Mol Biol"},{"key":"24_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2165\/00002512-199101020-00003","volume":"1","author":"RN Brogden","year":"1991","unstructured":"Brogden RN, Chrisp P (1991) Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer. Drugs Aging 1:104\u2013115","journal-title":"Drugs Aging"},{"key":"24_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2174\/138920209787581307","volume":"10","author":"GN Brooke","year":"2009","unstructured":"Brooke GN, Bevan CL (2009) The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 10:18\u201325","journal-title":"Curr Genomics"},{"key":"24_CR35","doi-asserted-by":"crossref","unstructured":"Brown J, Pan A, Hart RJ (2010) Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev, CD008475","DOI":"10.1002\/14651858.CD008475"},{"key":"24_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mce.2010.11.034","volume":"333","author":"L Busia","year":"2011","unstructured":"Busia L, Faus H, Hoffmann J, Haendler B (2011) The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by inducing p21 expression. Mol Cell Endocrinol 333:37\u201346","journal-title":"Mol Cell Endocrinol"},{"key":"24_CR37","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1210\/en.138.10.4147","volume":"138","author":"PE Chappell","year":"1997","unstructured":"Chappell PE, Lydon JP, Conneely OM, O\u2019Malley BW, Levine JE (1997) Endocrine defects in mice carrying a null mutation for the progesterone receptor gene. Endocrinology 138:4147\u20134152","journal-title":"Endocrinology"},{"key":"24_CR38","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.coph.2008.07.005","volume":"8","author":"Y Chen","year":"2008","unstructured":"Chen Y, Sawyers CL, Scher HI (2008) Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 8:440\u2013448","journal-title":"Curr Opin Pharmacol"},{"key":"24_CR39","doi-asserted-by":"crossref","first-page":"72","DOI":"10.7861\/clinmedicine.11-1-72","volume":"11","author":"A Clegg","year":"2011","unstructured":"Clegg A, Young J (2011) The frailty syndrome. Clin Med 11:72\u201375","journal-title":"Clin Med"},{"issue":"6","key":"24_CR40","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","volume":"72","author":"NJ Clegg","year":"2012","unstructured":"Clegg NJ, Wongvipat J, Tran C, Ouk S, Dilhas A, Joseph J, Chen Y, Grillot K, Bischoff ED, Cai L et al (2012) ARN-509: a novel anti-androgen for prostate cancer treatment. Cancer Res 72(6):1494\u2013503","journal-title":"Cancer Res"},{"key":"24_CR41","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2165\/00003495-200060020-00013","volume":"60","author":"D Clemett","year":"2000","unstructured":"Clemett D, Spencer CM (2000) Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 60:379\u2013411","journal-title":"Drugs"},{"key":"24_CR42","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2165\/00003088-200443130-00003","volume":"43","author":"ID Cockshott","year":"2004","unstructured":"Cockshott ID (2004) Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet 43:855\u2013878","journal-title":"Clin Pharmacokinet"},{"key":"24_CR43","doi-asserted-by":"publisher","first-page":"4880","DOI":"10.1021\/jm00025a004","volume":"38","author":"DW Combs","year":"1995","unstructured":"Combs DW, Reese K, Cornelius LA, Gunnet JW, Cryan EV, Granger KS, Jordan JJ, Demarest KT (1995) Nonsteroidal progesterone receptor ligands. 2. High-affinity ligands with selectivity for bone cell progesterone receptors. J Med Chem 38:4880\u20134884","journal-title":"J Med Chem"},{"key":"24_CR44","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1210\/rp.57.1.339","volume":"57","author":"OM Conneely","year":"2002","unstructured":"Conneely OM, Mulac-Jericevic B, DeMayo F, Lydon JP, O\u2019Malley BW (2002) Reproductive functions of progesterone receptors. Recent Prog Horm Res 57:339\u2013355","journal-title":"Recent Prog Horm Res"},{"key":"24_CR45","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0039-128X(03)00126-0","volume":"68","author":"OM Conneely","year":"2003","unstructured":"Conneely OM, Mulac-Jericevic B, Lydon JP (2003) Progesterone-dependent regulation of female reproductive activity by two distinct progesterone receptor isoforms. Steroids 68:771\u2013778","journal-title":"Steroids"},{"key":"24_CR46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/01720610-201101000-00009","volume":"24","author":"B Coplan","year":"2011","unstructured":"Coplan B, Spiegel J, Bleaman I, Roch J (2011) Testosterone replacement therapy: take an informed, individualized approach. JAAPA 24:42\u201347","journal-title":"JAAPA"},{"key":"24_CR47","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1743-6109.2010.02200.x","volume":"8","author":"G Corona","year":"2011","unstructured":"Corona G, Rastrelli G, Forti G, Maggi M (2011) Update in testosterone therapy for men. J Sex Med 8:639\u2013654, quiz 655","journal-title":"J Sex Med"},{"key":"24_CR48","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1210\/en.2005-0213","volume":"146","author":"JF Couse","year":"2005","unstructured":"Couse JF, Yates MM, Deroo BJ, Korach KS (2005) Estrogen receptor-beta is critical to granulosa cell differentiation and the ovulatory response to gonadotropins. Endocrinology 146:3247\u20133262","journal-title":"Endocrinology"},{"key":"24_CR49","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/ajcp\/94.4.435","volume":"94","author":"SF Cramer","year":"1990","unstructured":"Cramer SF, Patel A (1990) The frequency of uterine leiomyomas. Am J Clin Pathol 94:435\u2013438","journal-title":"Am J Clin Pathol"},{"key":"24_CR50","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1124\/pr.58.4.8","volume":"58","author":"K Dahlman-Wright","year":"2006","unstructured":"Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA (2006) International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 58:773\u2013781","journal-title":"Pharmacol Rev"},{"key":"24_CR51","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1742-1241.2010.02355.x","volume":"64","author":"P Dandona","year":"2010","unstructured":"Dandona P, Rosenberg MT (2010) A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract 64:682\u2013696","journal-title":"Int J Clin Pract"},{"key":"24_CR52","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.steroids.2003.09.008","volume":"68","author":"D DeManno","year":"2003","unstructured":"DeManno D, Elger W, Garg R, Lee R, Schneider B, Hess-Stumpp H, Schubert G, Chwalisz K (2003) Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 68:1019\u20131032","journal-title":"Steroids"},{"key":"24_CR53","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nrc801","volume":"2","author":"SR Denmeade","year":"2002","unstructured":"Denmeade SR, Isaacs JT (2002) A history of prostate cancer treatment. Nat Rev Cancer 2:389\u2013396","journal-title":"Nat Rev Cancer"},{"key":"24_CR54","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1210\/me.2009-0288","volume":"24","author":"BJ Deroo","year":"2010","unstructured":"Deroo BJ, Buensuceso AV (2010) Minireview: estrogen receptor-beta: mechanistic insights from recent studies. Mol Endocrinol 24:1703\u20131714","journal-title":"Mol Endocrinol"},{"key":"24_CR55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/106002809703100112","volume":"31","author":"EJ Dole","year":"1997","unstructured":"Dole EJ, Holdsworth MT (1997) Nilutamide: an antiandrogen for the treatment of prostate cancer. Ann Pharmacother 31:65\u201375","journal-title":"Ann Pharmacother"},{"key":"24_CR56","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.2165\/11207420-000000000-00000","volume":"71","author":"ST Duggan","year":"2011","unstructured":"Duggan ST, McKeage K (2011) Bazedoxifene: a review of its use in the treatment of postmenopausal osteoporosis. Drugs 71:2193\u20132212","journal-title":"Drugs"},{"key":"24_CR57","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1517\/14656566.2010.505920","volume":"11","author":"D Edelstein","year":"2010","unstructured":"Edelstein D, Basaria S (2010) Testosterone undecanoate in the treatment of male hypogonadism. Expert Opin Pharmacother 11:2095\u20132106","journal-title":"Expert Opin Pharmacother"},{"key":"24_CR58","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/med.1024","volume":"21","author":"U Egner","year":"2001","unstructured":"Egner U, Heinrich N, Ruff M, Gangloff M, Mueller-Fahrnow A, Wurtz JM (2001) Different ligands-different receptor conformations: modeling of the hER alpha LBD in complex with agonists and antagonists. Med Res Rev 21:523\u2013539","journal-title":"Med Res Rev"},{"key":"24_CR59","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/gye.17.2.169.176","volume":"17","author":"JM Emmen","year":"2003","unstructured":"Emmen JM, Korach KS (2003) Estrogen receptor knockout mice: phenotypes in the female reproductive tract. Gynecol Endocrinol 17:169\u2013176","journal-title":"Gynecol Endocrinol"},{"key":"24_CR60","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/ncpendmet0399","volume":"3","author":"JB Engel","year":"2007","unstructured":"Engel JB, Schally AV (2007) Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 3:157\u2013167","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"24_CR61","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","volume":"27","author":"WJ Evans","year":"2008","unstructured":"Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G et al (2008) Cachexia: a new definition. Clin Nutr 27:793\u2013799","journal-title":"Clin Nutr"},{"key":"24_CR62","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.biopha.2006.07.082","volume":"60","author":"H Faus","year":"2006","unstructured":"Faus H, Haendler B (2006) Post-translational modifications of steroid receptors. Biomed Pharmacother 60:520\u2013528","journal-title":"Biomed Pharmacother"},{"key":"24_CR63","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/35094009","volume":"1","author":"BJ Feldman","year":"2001","unstructured":"Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34\u201345","journal-title":"Nat Rev Cancer"},{"key":"24_CR64","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1021\/jm050358b","volume":"48","author":"A Fensome","year":"2005","unstructured":"Fensome A, Bender R, Chopra R, Cohen J, Collins MA, Hudak V, Malakian K, Lockhead S, Olland A, Svenson K et al (2005) Synthesis and structure-activity relationship of novel 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading to the potent and selective nonsteroidal progesterone receptor agonist tanaproget. J Med Chem 48:5092\u20135095","journal-title":"J Med Chem"},{"key":"24_CR65","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1055\/s-2005-864031","volume":"23","author":"R Fernandez-Valdivia","year":"2005","unstructured":"Fernandez-Valdivia R, Mukherjee A, Mulac-Jericevic B, Conneely OM, DeMayo FJ, Amato P, Lydon JP (2005) Revealing progesterone\u2019s role in uterine and mammary gland biology: insights from the mouse. Semin Reprod Med 23:22\u201337","journal-title":"Semin Reprod Med"},{"key":"24_CR66","doi-asserted-by":"crossref","unstructured":"Findlay JK, Liew SH, Simpson ER, Korach KS (2010) Estrogen signaling in the regulation of female reproductive functions. Handb Exp Pharmacol. 29\u201335","DOI":"10.1007\/978-3-642-02062-9_2"},{"key":"24_CR67","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1097\/01.AOG.0000243776.23391.7b","volume":"108","author":"K Fiscella","year":"2006","unstructured":"Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS (2006) Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 108:1381\u20131387","journal-title":"Obstet Gynecol"},{"key":"24_CR68","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/jcp.22159","volume":"224","author":"B Frenkel","year":"2010","unstructured":"Frenkel B, Hong A, Baniwal SK, Coetzee GA, Ohlsson C, Khalid O, Gabet Y (2010) Regulation of adult bone turnover by sex steroids. J Cell Physiol 224:305\u2013310","journal-title":"J Cell Physiol"},{"key":"24_CR69","doi-asserted-by":"crossref","unstructured":"Fritzemeier KH, Hillisch A, Elger W, Kaufmann U, Kollenkirchen U, Kosemund D, Lindenthal B, Muller G, Muhn P, Nubbemeyer R, et al. (2004) Biological effects of ERalpha- and ERbeta-selective estrogens. Ernst Schering Res Found Workshop, 127\u2013150","DOI":"10.1007\/978-3-662-05386-7_9"},{"key":"24_CR70","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1021\/jm001000c","volume":"43","author":"U Fuhrmann","year":"2000","unstructured":"Fuhrmann U, Hess-Stumpp H, Cleve A, Neef G, Schwede W, Hoffmann J, Fritzemeier KH, Chwalisz K (2000) Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem 43:5010\u20135016","journal-title":"J Med Chem"},{"key":"24_CR71","doi-asserted-by":"crossref","unstructured":"Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF (2011) 20 microg versus >20 microg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev, CD003989","DOI":"10.1002\/14651858.CD003989.pub4"},{"key":"24_CR72","doi-asserted-by":"publisher","first-page":"4887","DOI":"10.1210\/en.2005-0572","volume":"146","author":"W Gao","year":"2005","unstructured":"Gao W, Reiser PJ, Coss CC, Phelps MA, Kearbey JD, Miller DD, Dalton JT (2005) Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 146:4887\u20134897","journal-title":"Endocrinology"},{"key":"24_CR73","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2741\/1821","volume":"11","author":"J Garai","year":"2006","unstructured":"Garai J, Molnar V, Varga T, Koppan M, Torok A, Bodis J (2006) Endometriosis: harmful survival of an ectopic tissue. Front Biosci 11:595\u2013619","journal-title":"Front Biosci"},{"key":"24_CR74","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.1210\/en.2005-0024","volume":"146","author":"AG Geiser","year":"2005","unstructured":"Geiser AG, Hummel CW, Draper MW, Henck JW, Cohen IR, Rudmann DG, Donnelly KB, Adrian MD, Shepherd TA, Wallace OB et al (2005) A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation. Endocrinology 146:4524\u20134535","journal-title":"Endocrinology"},{"key":"24_CR75","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00216-010-4569-8","volume":"400","author":"E Gerace","year":"2010","unstructured":"Gerace E, Salomone A, Fasano F, Costa R, Boschi D, Di Stilo A, Vincenti M (2010) Validation of a GC\/MS method for the detection of two quinolinone-derived selective androgen receptor modulators in doping control analysis. Anal Bioanal Chem 400:137\u201344","journal-title":"Anal Bioanal Chem"},{"key":"24_CR76","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000175842","volume":"37","author":"LJ Gooren","year":"2009","unstructured":"Gooren LJ (2009) Advances in testosterone replacement therapy. Front Horm Res 37:32\u201351","journal-title":"Front Horm Res"},{"key":"24_CR77","first-page":"63","volume":"260","author":"UF Habenicht","year":"1988","unstructured":"Habenicht UF, Schroder H, el Etreby MF, Neumann F (1988) Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer. Prog Clin Biol Res 260:63\u201375","journal-title":"Prog Clin Biol Res"},{"key":"24_CR78","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.mce.2011.06.002","volume":"352","author":"B Haendler","year":"2011","unstructured":"Haendler B, Cleve A (2011) Recent developments in antiandrogens and selective androgen receptor modulators. Mol Cell Endocrinol 352:79\u201391","journal-title":"Mol Cell Endocrinol"},{"key":"24_CR79","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1210\/er.2007-0022","volume":"28","author":"SR Hammes","year":"2007","unstructured":"Hammes SR, Levin ER (2007) Extranuclear steroid receptors: nature and actions. Endocr Rev 28:726\u2013741","journal-title":"Endocr Rev"},{"key":"24_CR80","doi-asserted-by":"crossref","unstructured":"Harris HA (2006) Preclinical characterization of selective estrogen receptor beta agonists: new insights into their therapeutic potential. Ernst Schering Found Symp Proc, 149\u2013161","DOI":"10.1007\/2789_2006_021"},{"key":"24_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/me.2005-0459","volume":"21","author":"HA Harris","year":"2007","unstructured":"Harris HA (2007) Estrogen receptor-beta: recent lessons from in vivo studies. Mol Endocrinol 21:1\u201313","journal-title":"Mol Endocrinol"},{"key":"24_CR82","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1073\/pnas.0306720101","volume":"101","author":"C Hegele-Hartung","year":"2004","unstructured":"Hegele-Hartung C, Siebel P, Peters O, Kosemund D, Muller G, Hillisch A, Walter A, Kraetzschmar J, Fritzemeier KH (2004) Impact of isotype-selective estrogen receptor agonists on ovarian function. Proc Natl Acad Sci USA 101:5129\u20135134","journal-title":"Proc Natl Acad Sci USA"},{"key":"24_CR83","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1210\/me.2004-0050","volume":"18","author":"A Hillisch","year":"2004","unstructured":"Hillisch A, Peters O, Kosemund D, Muller G, Walter A, Schneider B, Reddersen G, Elger W, Fritzemeier KH (2004) Dissecting physiological roles of estrogen receptor alpha and beta with potent selective ligands from structure-based design. Mol Endocrinol 18:1599\u20131609","journal-title":"Mol Endocrinol"},{"key":"24_CR84","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1136\/jcp.2010.076968","volume":"64","author":"CK Ho","year":"2011","unstructured":"Ho CK, Beckett GJ (2011) Late-onset male hypogonadism: clinical and laboratory evaluation. J Clin Pathol 64:459\u2013465","journal-title":"J Clin Pathol"},{"key":"24_CR85","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/jnci\/djh022","volume":"96","author":"J Hoffmann","year":"2004","unstructured":"Hoffmann J, Bohlmann R, Heinrich N, Hofmeister H, Kroll J, Kunzer H, Lichtner RB, Nishino Y, Parczyk K, Sauer G et al (2004) Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer. J Natl Cancer Inst 96:210\u2013218","journal-title":"J Natl Cancer Inst"},{"key":"24_CR86","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1055\/s-0028-1118635","volume":"72","author":"W Hohlweg","year":"1947","unstructured":"Hohlweg W, Inhoffen HH (1947) Not available. Dtsch Med Wochenschr 72:86","journal-title":"Dtsch Med Wochenschr"},{"key":"24_CR87","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1210\/endo-113-6-2195","volume":"113","author":"KB Horwitz","year":"1983","unstructured":"Horwitz KB, Alexander PS (1983) In situ photolinked nuclear progesterone receptors of human breast cancer cells: subunit molecular weights after transformation and translocation. Endocrinology 113:2195\u20132201","journal-title":"Endocrinology"},{"key":"24_CR88","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1210\/me.2009-0238","volume":"24","author":"Y Imai","year":"2010","unstructured":"Imai Y, Kondoh S, Kouzmenko A, Kato S (2010) Minireview: osteoprotective action of estrogens is mediated by osteoclastic estrogen receptor-alpha. Mol Endocrinol 24:877\u2013885","journal-title":"Mol Endocrinol"},{"key":"24_CR89","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/modpathol.2008.204","volume":"22","author":"OB Ioffe","year":"2009","unstructured":"Ioffe OB, Zaino RJ, Mutter GL (2009) Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Mod Pathol 22:450\u2013459","journal-title":"Mod Pathol"},{"key":"24_CR90","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.physbeh.2009.08.013","volume":"99","author":"EV Jensen","year":"2010","unstructured":"Jensen EV, Jacobson HI, Walf AA, Frye CA (2010) Estrogen action: a historic perspective on the implications of considering alternative approaches. Physiol Behav 99:151\u2013162","journal-title":"Physiol Behav"},{"key":"24_CR91","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1373\/clinchem.2010.143297","volume":"56","author":"Y Jiang","year":"2010","unstructured":"Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME (2010) Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 56:1492\u20131495","journal-title":"Clin Chem"},{"key":"24_CR92","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0029-7844(01)01433-8","volume":"98","author":"G Jones","year":"2001","unstructured":"Jones G, Kennedy S, Barnard A, Wong J, Jenkinson C (2001) Development of an endometriosis quality-of-life instrument: the endometriosis health profile-30. Obstet Gynecol 98:258\u2013264","journal-title":"Obstet Gynecol"},{"key":"24_CR93","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1016\/j.bmcl.2005.05.001","volume":"15","author":"DG Jones","year":"2005","unstructured":"Jones DG, Liang X, Stewart EL, Noe RA, Kallander LS, Madauss KP, Williams SP, Thompson SK, Gray DW, Hoekstra WJ (2005) Discovery of non-steroidal mifepristone mimetics: pyrazoline-based PR antagonists. Bioorg Med Chem Lett 15:3203\u20133206","journal-title":"Bioorg Med Chem Lett"},{"key":"24_CR94","first-page":"7","volume":"11","author":"VC Jordan","year":"1997","unstructured":"Jordan VC (1997) Tamoxifen treatment for breast cancer: concept to gold standard. Oncology (Williston Park) 11:7\u201313","journal-title":"Oncology (Williston Park)"},{"key":"24_CR95","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/bies.20676","volume":"29","author":"M Kaarbo","year":"2007","unstructured":"Kaarbo M, Klokk TI, Saatcioglu F (2007) Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays 29:1227\u20131238","journal-title":"Bioessays"},{"key":"24_CR96","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.bmcl.2009.10.092","volume":"20","author":"LS Kallander","year":"2010","unstructured":"Kallander LS, Washburn DG, Hoang TH, Frazee JS, Stoy P, Johnson L, Lu Q, Hammond M, Barton LS, Patterson JR et al (2010) Improving the developability profile of pyrrolidine progesterone receptor partial agonists. Bioorg Med Chem Lett 20:371\u2013374","journal-title":"Bioorg Med Chem Lett"},{"key":"24_CR97","first-page":"415","volume":"62","author":"D Kappou","year":"2010","unstructured":"Kappou D, Matalliotakis M, Matalliotakis I (2010) Medical treatments for endometriosis. Minerva Ginecol 62:415\u2013432","journal-title":"Minerva Ginecol"},{"key":"24_CR98","first-page":"163","volume":"55","author":"BS Katzenellenbogen","year":"2000","unstructured":"Katzenellenbogen BS, Montano MM, Ediger TR, Sun J, Ekena K, Lazennec G, Martini PG, McInerney EM, Delage-Mourroux R, Weis K, Katzenellenbogen JA (2000) Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res 55:163\u2013193, discussion 194\u2013165","journal-title":"Recent Prog Horm Res"},{"key":"24_CR99","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s11095-006-9152-9","volume":"24","author":"JD Kearbey","year":"2007","unstructured":"Kearbey JD, Gao W, Narayanan R, Fisher SJ, Wu D, Miller DD, Dalton JT (2007) Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res 24:328\u2013335","journal-title":"Pharm Res"},{"key":"24_CR100","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0015-0282(16)54531-2","volume":"56","author":"LM Kettel","year":"1991","unstructured":"Kettel LM, Murphy AA, Mortola JF, Liu JH, Ulmann A, Yen SS (1991) Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Fertil Steril 56:402\u2013407","journal-title":"Fertil Steril"},{"key":"24_CR101","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0015-0282(16)58022-4","volume":"65","author":"LM Kettel","year":"1996","unstructured":"Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SS (1996) Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 65:23\u201328","journal-title":"Fertil Steril"},{"key":"24_CR102","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S0002-9378(98)70316-3","volume":"178","author":"LM Kettel","year":"1998","unstructured":"Kettel LM, Murphy AA, Morales AJ, Yen SS (1998) Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 178:1151\u20131156","journal-title":"Am J Obstet Gynecol"},{"key":"24_CR103","first-page":"821","volume":"8","author":"EJ Kilbourne","year":"2007","unstructured":"Kilbourne EJ, Moore WJ, Freedman LP, Nagpal S (2007) Selective androgen receptor modulators for frailty and osteoporosis. Curr Opin Investig Drugs 8:821\u2013829","journal-title":"Curr Opin Investig Drugs"},{"issue":"Suppl 1","key":"24_CR104","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/humrep\/9.suppl_1.181","volume":"9","author":"JG Klijn","year":"1994","unstructured":"Klijn JG, Setyono-Han B, Sander HJ, Lamberts SW, de Jong FH, Deckers GH, Foekens JA (1994) Pre-clinical and clinical treatment of breast cancer with antiprogestins. Hum Reprod 9(Suppl 1):181\u2013189","journal-title":"Hum Reprod"},{"key":"24_CR105","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0039-128X(00)00195-1","volume":"65","author":"JG Klijn","year":"2000","unstructured":"Klijn JG, Setyono-Han B, Foekens JA (2000) Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids 65:825\u2013830","journal-title":"Steroids"},{"key":"24_CR106","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.tem.2010.01.002","volume":"21","author":"KE Knudsen","year":"2010","unstructured":"Knudsen KE, Penning TM (2010) Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 21:315\u2013324","journal-title":"Trends Endocrinol Metab"},{"key":"24_CR107","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1517\/14656566.2011.557360","volume":"12","author":"SS Ko","year":"2011","unstructured":"Ko SS, Jordan VC (2011) Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert Opin Pharmacother 12:657\u2013674","journal-title":"Expert Opin Pharmacother"},{"key":"24_CR108","first-page":"551","volume":"43","author":"SS Koide","year":"1998","unstructured":"Koide SS (1998) Mifepristone. Auxiliary therapeutic use in cancer and related disorders. J Reprod Med 43:551\u2013560","journal-title":"J Reprod Med"},{"key":"24_CR109","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/msb.2010.102","volume":"6","author":"AN Kolodkin","year":"2010","unstructured":"Kolodkin AN, Bruggeman FJ, Plant N, Mone MJ, Bakker BM, Campbell MJ, van Leeuwen JP, Carlberg C, Snoep JL, Westerhoff HV (2010) Design principles of nuclear receptor signaling: how complex networking improves signal transduction. Mol Syst Biol 6:446","journal-title":"Mol Syst Biol"},{"key":"24_CR110","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.mce.2005.11.028","volume":"246","author":"S Kumar","year":"2006","unstructured":"Kumar S, Saradhi M, Chaturvedi NK, Tyagi RK (2006) Intracellular localization and nucleocytoplasmic trafficking of steroid receptors: an overview. Mol Cell Endocrinol 246:147\u2013156","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"24_CR111","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrurol.2010.231","volume":"8","author":"F Labrie","year":"2011","unstructured":"Labrie F (2011) Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol 8(2):73\u201385","journal-title":"Nat Rev Urol"},{"key":"24_CR112","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.1210\/en.2003-0269","volume":"144","author":"F Labrie","year":"2003","unstructured":"Labrie F, El-Alfy M, Berger L, Labrie C, Martel C, Belanger A, Candas B, Pelletier G (2003) The combination of a novel selective estrogen receptor modulator with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women\u2019s health? Endocrinology 144:4700\u20134706","journal-title":"Endocrinology"},{"key":"24_CR113","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1146\/annurev.physiol.69.031905.160319","volume":"69","author":"CA Lange","year":"2007","unstructured":"Lange CA, Gioeli D, Hammes SR, Marker PC (2007) Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer. Annu Rev Physiol 69:171\u2013199","journal-title":"Annu Rev Physiol"},{"key":"24_CR114","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.steroids.2009.12.006","volume":"75","author":"G Langer","year":"2010","unstructured":"Langer G, Bader B, Meoli L, Isensee J, Delbeck M, Noppinger PR, Otto C (2010) A critical review of fundamental controversies in the field of GPR30 research. Steroids 75:603\u2013610","journal-title":"Steroids"},{"key":"24_CR115","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1055\/s-0030-1251477","volume":"28","author":"SK Laughlin","year":"2010","unstructured":"Laughlin SK, Schroeder JC, Baird DD (2010) New directions in the epidemiology of uterine fibroids. Semin Reprod Med 28:204\u2013217","journal-title":"Semin Reprod Med"},{"key":"24_CR116","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/BF03345775","volume":"32","author":"A Lenzi","year":"2009","unstructured":"Lenzi A, Balercia G, Bellastella A, Colao A, Fabbri A, Foresta C, Galdiero M, Gandini L, Krausz C, Lombardi G et al (2009) Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism. J Endocrinol Invest 32:934\u2013938","journal-title":"J Endocrinol Invest"},{"key":"24_CR117","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.maturitas.2009.03.008","volume":"63","author":"J Li","year":"2009","unstructured":"Li J, Al-Azzawi F (2009) Mechanism of androgen receptor action. Maturitas 63:142\u2013148","journal-title":"Maturitas"},{"key":"24_CR118","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0039-128X(01)00133-7","volume":"67","author":"DM Lonard","year":"2002","unstructured":"Lonard DM, Smith CL (2002) Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions. Steroids 67:15\u201324","journal-title":"Steroids"},{"key":"24_CR119","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1152\/physrev.00003.2003","volume":"83","author":"RM Losel","year":"2003","unstructured":"Losel RM, Falkenstein E, Feuring M, Schultz A, Tillmann HC, Rossol-Haseroth K, Wehling M (2003) Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 83:965\u20131016","journal-title":"Physiol Rev"},{"key":"24_CR120","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1101\/gad.9.18.2266","volume":"9","author":"JP Lydon","year":"1995","unstructured":"Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA Jr, Shyamala G, Conneely OM, O\u2019Malley BW (1995) Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 9:2266\u20132278","journal-title":"Genes Dev"},{"key":"24_CR121","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2217\/whe.10.84","volume":"7","author":"RB Machado","year":"2011","unstructured":"Machado RB, Pompei Lde M, Giribela AG, Giribela CG (2011) Drospirenone\/ethinylestradiol: a review on efficacy and noncontraceptive benefits. Womens Health (Lond Engl) 7:19\u201330","journal-title":"Womens Health (Lond Engl)"},{"key":"24_CR122","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.ajog.2011.06.056","volume":"205","author":"K Maguire","year":"2011","unstructured":"Maguire K, Westhoff C (2011) The state of hormonal contraception today: established and emerging noncontraceptive health benefits. Am J Obstet Gynecol 205:S4\u20138","journal-title":"Am J Obstet Gynecol"},{"key":"24_CR123","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/0092-8674(95)90199-X","volume":"83","author":"DJ Mangelsdorf","year":"1995","unstructured":"Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM (1995) The nuclear receptor superfamily: the second decade. Cell 83:835\u2013839","journal-title":"Cell"},{"key":"24_CR124","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10549-007-9507-x","volume":"106","author":"R Mansel","year":"2007","unstructured":"Mansel R, Goyal A, Nestour EL, Masini-Eteve V, O\u2019Connell K (2007) A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women. Breast Cancer Res Treat 106:389\u2013397","journal-title":"Breast Cancer Res Treat"},{"key":"24_CR125","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1021\/jm070231h","volume":"50","author":"E Martinborough","year":"2007","unstructured":"Martinborough E, Shen Y, Oeveren A, Long YO, Lau TL, Marschke KB, Chang WY, Lopez FJ, Vajda EG, Rix PJ et al (2007) Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators. J Med Chem 50:5049\u20135052","journal-title":"J Med Chem"},{"key":"24_CR126","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jsbmb.2008.03.023","volume":"109","author":"T Matsumoto","year":"2008","unstructured":"Matsumoto T, Shiina H, Kawano H, Sato T, Kato S (2008) Androgen receptor functions in male and female physiology. J Steroid Biochem Mol Biol 109:236\u2013241","journal-title":"J Steroid Biochem Mol Biol"},{"key":"24_CR127","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11207410-000000000-00000","volume":"71","author":"K McKeage","year":"2011","unstructured":"McKeage K, Croxtall JD (2011) Ulipristal acetate: a review of its use in emergency contraception. Drugs 71:935\u2013945","journal-title":"Drugs"},{"key":"24_CR128","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/0010-7824(91)90151-5","volume":"44","author":"VL McLaurin","year":"1991","unstructured":"McLaurin VL, Dunson BA, Dunson TR (1991) A comparative study of 35\u00a0mcg and 50\u00a0mcg combined oral contraceptives: results from a multicenter clinical trial. Contraception 44:489\u2013503","journal-title":"Contraception"},{"key":"24_CR129","doi-asserted-by":"crossref","unstructured":"McPherson SJ, Ellem SJ, Patchev V, Fritzemeier KH, Risbridger GP (2006) The role of Eralpha and ERbeta in the prostate: insights from genetic models and isoform-selective ligands. Ernst Schering Found Symp Proc, 131\u2013147","DOI":"10.1007\/2789_2006_020"},{"key":"24_CR130","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1210\/en.2006-0906","volume":"148","author":"SJ McPherson","year":"2007","unstructured":"McPherson SJ, Ellem SJ, Simpson ER, Patchev V, Fritzemeier KH, Risbridger GP (2007) Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology 148:566\u2013574","journal-title":"Endocrinology"},{"key":"24_CR131","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1073\/pnas.0905524107","volume":"107","author":"SJ McPherson","year":"2010","unstructured":"McPherson SJ, Hussain S, Balanathan P, Hedwards SL, Niranjan B, Grant M, Chandrasiri UP, Toivanen R, Wang Y, Taylor RA, Risbridger GP (2010) Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci USA 107:3123\u20133128","journal-title":"Proc Natl Acad Sci USA"},{"key":"24_CR132","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1210\/er.2010-0013","volume":"32","author":"WL Miller","year":"2011","unstructured":"Miller WL, Auchus RJ (2011) The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 32:81\u2013151","journal-title":"Endocr Rev"},{"key":"24_CR133","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/med.20186","volume":"31","author":"F Minutolo","year":"2011","unstructured":"Minutolo F, Macchia M, Katzenellenbogen BS, Katzenellenbogen JA (2011) Estrogen receptor beta ligands: recent advances and biomedical applications. Med Res Rev 31:364\u2013442","journal-title":"Med Res Rev"},{"key":"24_CR134","doi-asserted-by":"publisher","first-page":"H295","DOI":"10.1152\/ajpheart.00468.2005","volume":"290","author":"RG Mishra","year":"2006","unstructured":"Mishra RG, Stanczyk FZ, Burry KA, Oparil S, Katzenellenbogen BS, Nealen ML, Katzenellenbogen JA, Hermsmeyer RK (2006) Metabolite ligands of estrogen receptor-beta reduce primate coronary hyperreactivity. Am J Physiol Heart Circ Physiol 290:H295\u2013303","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"24_CR135","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jcb.10757","volume":"91","author":"H Miyamoto","year":"2004","unstructured":"Miyamoto H, Rahman MM, Chang C (2004) Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem 91:3\u201312","journal-title":"J Cell Biochem"},{"key":"24_CR136","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1021\/jm900280m","volume":"52","author":"ML Mohler","year":"2009","unstructured":"Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, Hwang DJ, Dalton JT, Miller DD (2009) Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem 52:3597\u20133617","journal-title":"J Med Chem"},{"key":"24_CR137","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1517\/13543771003657164","volume":"20","author":"ML Mohler","year":"2010","unstructured":"Mohler ML, Narayanan R, Coss CC, Hu K, He Y, Wu Z, Hong SS, Hwang DJ, Miller DD, Dalton JT (2010) Estrogen receptor beta selective nonsteroidal estrogens: seeking clinical indications. Expert Opin Ther Pat 20:507\u2013534","journal-title":"Expert Opin Ther Pat"},{"key":"24_CR138","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","volume":"68","author":"RB Montgomery","year":"2008","unstructured":"Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68:4447\u20134454","journal-title":"Cancer Res"},{"key":"24_CR139","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1365-2796.2008.01976.x","volume":"264","author":"A Morani","year":"2008","unstructured":"Morani A, Warner M, Gustafsson JA (2008) Biological functions and clinical implications of oestrogen receptors alfa and beta in epithelial tissues. J Intern Med 264:128\u2013142","journal-title":"J Intern Med"},{"key":"24_CR140","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1677\/erc.0.0090267","volume":"9","author":"C Morris","year":"2002","unstructured":"Morris C, Wakeling A (2002) Fulvestrant (\u2018Faslodex\u2019)\u2013a new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer 9:267\u2013276","journal-title":"Endocr Relat Cancer"},{"key":"24_CR141","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/0277-5379(83)90164-5","volume":"19","author":"HT Mouridsen","year":"1983","unstructured":"Mouridsen HT, Palshof T (1983) Adjuvant systemic therapy in breast cancer; a review. Eur J Cancer Clin Oncol 19:1753\u20131770","journal-title":"Eur J Cancer Clin Oncol"},{"key":"24_CR142","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/toxsci\/kfh147","volume":"80","author":"SO Mueller","year":"2004","unstructured":"Mueller SO, Simon S, Chae K, Metzler M, Korach KS (2004) Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 80:14\u201325","journal-title":"Toxicol Sci"},{"key":"24_CR143","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1517\/13543784.2012.651125","volume":"21","author":"D Mukherji","year":"2012","unstructured":"Mukherji D, Pezaro CJ, De-Bono JS (2012) MDV3100 for the treatment of prostate cancer. Expert Opin Investig Drugs 21:227\u2013233","journal-title":"Expert Opin Investig Drugs"},{"key":"24_CR144","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1126\/science.289.5485.1751","volume":"289","author":"B Mulac-Jericevic","year":"2000","unstructured":"Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM (2000) Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 289:1751\u20131754","journal-title":"Science"},{"key":"24_CR145","doi-asserted-by":"publisher","first-page":"9744","DOI":"10.1073\/pnas.1732707100","volume":"100","author":"B Mulac-Jericevic","year":"2003","unstructured":"Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM (2003) Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci USA 100:9744\u20139749","journal-title":"Proc Natl Acad Sci USA"},{"key":"24_CR146","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2174\/092986707780598023","volume":"14","author":"MA Musa","year":"2007","unstructured":"Musa MA, Khan MO, Cooperwood JS (2007) Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs). Curr Med Chem 14:1249\u20131261","journal-title":"Curr Med Chem"},{"key":"24_CR147","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1210\/me.2008-0160","volume":"22","author":"R Narayanan","year":"2008","unstructured":"Narayanan R, Coss CC, Yepuru M, Kearbey JD, Miller DD, Dalton JT (2008a) Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol 22:2448\u20132465","journal-title":"Mol Endocrinol"},{"key":"24_CR148","doi-asserted-by":"crossref","first-page":"e010","DOI":"10.1621\/nrs.06010","volume":"6","author":"R Narayanan","year":"2008","unstructured":"Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT (2008b) Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal 6:e010","journal-title":"Nucl Recept Signal"},{"key":"24_CR149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1055\/s-0029-1211261","volume":"102","author":"F Neumann","year":"1994","unstructured":"Neumann F (1994) The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp Clin Endocrinol 102:1\u201332","journal-title":"Exp Clin Endocrinol"},{"key":"24_CR150","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1365-2265.2006.02618.x","volume":"65","author":"E Nieschlag","year":"2006","unstructured":"Nieschlag E (2006) Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf) 65:275\u2013281","journal-title":"Clin Endocrinol (Oxf)"},{"key":"24_CR151","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/humupd\/dmh035","volume":"10","author":"E Nieschlag","year":"2004","unstructured":"Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, Webb SM, Wu FC (2004) Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 10:409\u2013419","journal-title":"Hum Reprod Update"},{"key":"24_CR152","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/clpt.2010.226","volume":"89","author":"S Nilsson","year":"2011","unstructured":"Nilsson S, Gustafsson JA (2011) Estrogen receptors: therapies targeted to receptor subtypes. Clin Pharmacol Ther 89:44\u201355","journal-title":"Clin Pharmacol Ther"},{"key":"24_CR153","first-page":"17","volume":"62","author":"WB Nothnick","year":"2010","unstructured":"Nothnick WB (2010) Endometriosis: in search of optimal treatment. Minerva Ginecol 62:17\u201331","journal-title":"Minerva Ginecol"},{"key":"24_CR154","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.bpobgyn.2008.04.002","volume":"22","author":"S Okolo","year":"2008","unstructured":"Okolo S (2008) Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 22:571\u2013588","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"24_CR155","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00001703-200406000-00006","volume":"16","author":"DL Olive","year":"2004","unstructured":"Olive DL, Lindheim SR, Pritts EA (2004) Non-surgical management of leiomyoma: impact on fertility. Curr Opin Obstet Gynecol 16:239\u2013243","journal-title":"Curr Opin Obstet Gynecol"},{"key":"24_CR156","first-page":"3","volume":"25","author":"D Onken","year":"1970","unstructured":"Onken D, Heublein D (1970) Ethinylated steroids. Pharmazie 25:3\u20139","journal-title":"Pharmazie"},{"key":"24_CR157","first-page":"859","volume":"8","author":"PA Orihuela","year":"2007","unstructured":"Orihuela PA (2007) Ulipristal, a progesterone receptor antagonist as a contraceptive and for the treatment of uterine fibroids. Curr Opin Investig Drugs 8:859\u2013866","journal-title":"Curr Opin Investig Drugs"},{"key":"24_CR158","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","volume":"62","author":"CK Osborne","year":"2011","unstructured":"Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233\u2013247","journal-title":"Annu Rev Med"},{"issue":"Suppl 1","key":"24_CR159","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/sj.bjc.6601629","volume":"90","author":"CK Osborne","year":"2004","unstructured":"Osborne CK, Wakeling A, Nicholson RI (2004) Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 90(Suppl 1):S2\u20136","journal-title":"Br J Cancer"},{"key":"24_CR160","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/en.2006-0843","volume":"148","author":"J Ostrowski","year":"2007","unstructured":"Ostrowski J, Kuhns JE, Lupisella JA, Manfredi MC, Beehler BC, Krystek SR Jr, Bi Y, Sun C, Seethala R, Golla R et al (2007) Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology 148:4\u201312","journal-title":"Endocrinology"},{"key":"24_CR161","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.maturitas.2010.10.009","volume":"68","author":"SK Pal","year":"2011","unstructured":"Pal SK, Sartor O (2011) Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. Maturitas 68:103\u2013105","journal-title":"Maturitas"},{"key":"24_CR162","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0960-0760(00)00134-5","volume":"75","author":"S Palmer","year":"2000","unstructured":"Palmer S, Campen CA, Allan GF, Rybczynski P, Haynes-Johnson D, Hutchins A, Kraft P, Kiddoe M, Lai M, Lombardi E et al (2000) Nonsteroidal progesterone receptor ligands with unprecedented receptor selectivity. J Steroid Biochem Mol Biol 75:33\u201342","journal-title":"J Steroid Biochem Mol Biol"},{"key":"24_CR163","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1517\/14712598.2010.503773","volume":"10","author":"F Penna","year":"2010","unstructured":"Penna F, Minero VG, Costamagna D, Bonelli G, Baccino FM, Costelli P (2010) Anti-cytokine strategies for the treatment of cancer-related anorexia and cachexia. Expert Opin Biol Ther 10:1241\u20131250","journal-title":"Expert Opin Biol Ther"},{"key":"24_CR164","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/1933719110367829","volume":"17","author":"FR Perez-Lopez","year":"2010","unstructured":"Perez-Lopez FR, Larrad-Mur L, Kallen A, Chedraui P, Taylor HS (2010) Gender differences in cardiovascular disease: hormonal and biochemical influences. Reprod Sci 17:511\u2013531","journal-title":"Reprod Sci"},{"key":"24_CR165","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nrg2736","volume":"11","author":"V Perissi","year":"2010","unstructured":"Perissi V, Jepsen K, Glass CK, Rosenfeld MG (2010) Deconstructing repression: evolving models of co-repressor action. Nat Rev Genet 11:109\u2013123","journal-title":"Nat Rev Genet"},{"key":"24_CR166","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.drudis.2011.12.012","volume":"17","author":"CJ Pezaro","year":"2011","unstructured":"Pezaro CJ, Mukherji D, De Bono JS (2011) Abiraterone acetate: redefining hormone treatment for advanced prostate cancer. Drug Discov Today 17:221\u20136","journal-title":"Drug Discov Today"},{"key":"24_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.beem.2005.09.002","volume":"20","author":"AC Pike","year":"2006","unstructured":"Pike AC (2006) Lessons learnt from structural studies of the oestrogen receptor. Best Pract Res Clin Endocrinol Metab 20:1\u201314","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"24_CR168","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1042\/bse0400041","volume":"40","author":"WB Pratt","year":"2004","unstructured":"Pratt WB, Galigniana MD, Morishima Y, Murphy PJ (2004) Role of molecular chaperones in steroid receptor action. Essays Biochem 40:41\u201358","journal-title":"Essays Biochem"},{"key":"24_CR169","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1517\/14656566.8.7.989","volume":"8","author":"AJ Rapkin","year":"2007","unstructured":"Rapkin AJ, Winer SA (2007) Drospirenone: a novel progestin. Expert Opin Pharmacother 8:989\u2013999","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"24_CR170","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1158\/1078-0432.CCR-10-2955","volume":"17","author":"D Rathkopf","year":"2010","unstructured":"Rathkopf D, Liu G, Carducci MA, Eisenberger MA, Anand A, Morris M, Slovin SF, Sasaki Y, Takahashi S, Ozono S et al (2010) Phase I Dose-Escalation Study of the Novel Anti-androgen BMS-641988 in Patients with Castration-Resistant Prostate Cancer. Clin Cancer Res 17(4):880\u20137","journal-title":"Clin Cancer Res"},{"key":"24_CR171","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1185\/03007995.2011.606312","volume":"27","author":"RR Recker","year":"2011","unstructured":"Recker RR, Mitlak BH, Ni X, Krege JH (2011) Long-term raloxifene for postmenopausal osteoporosis. Curr Med Res Opin 27:1755\u20131761","journal-title":"Curr Med Res Opin"},{"key":"24_CR172","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.coph.2006.10.009","volume":"7","author":"V Regitz-Zagrosek","year":"2007","unstructured":"Regitz-Zagrosek V, Wintermantel TM, Schubert C (2007) Estrogens and SERMs in coronary heart disease. Curr Opin Pharmacol 7:130\u2013139","journal-title":"Curr Opin Pharmacol"},{"key":"24_CR173","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S1097-2765(03)00090-X","volume":"11","author":"G Reid","year":"2003","unstructured":"Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F (2003) Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11:695\u2013707","journal-title":"Mol Cell"},{"key":"24_CR174","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S0959-8049(98)00388-8","volume":"35","author":"JF Robertson","year":"1999","unstructured":"Robertson JF, Willsher PC, Winterbottom L, Blamey RW, Thorpe S (1999) Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer 35:214\u2013218","journal-title":"Eur J Cancer"},{"key":"24_CR175","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/acr.20275","volume":"62","author":"JA Roman-Blas","year":"2010","unstructured":"Roman-Blas JA, Castaneda S, Cutolo M, Herrero-Beaumont G (2010) Efficacy and safety of a selective estrogen receptor beta agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study. Arthritis Care Res (Hoboken) 62:1588\u20131593","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"24_CR176","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1200\/JCO.2011.35.2005","volume":"29","author":"CJ Ryan","year":"2011","unstructured":"Ryan CJ, Tindall DJ (2011) Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 29:3651\u20133658","journal-title":"J Clin Oncol"},{"key":"24_CR177","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1472-8206.2010.00916.x","volume":"26","author":"L Saha","year":"2012","unstructured":"Saha L, Kaur S, Saha PK (2012) Pharmacotherapy of polycystic ovary syndrome \u2014 an update. Fundam Clin Pharmacol 26:54\u201362","journal-title":"Fundam Clin Pharmacol"},{"key":"24_CR178","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1196\/annals.1290.039","volume":"997","author":"G Samsioe","year":"2003","unstructured":"Samsioe G (2003) HRT and cardiovascular disease. Ann N Y Acad Sci 997:358\u2013372","journal-title":"Ann N Y Acad Sci"},{"key":"24_CR179","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1210\/me.8.10.1347","volume":"8","author":"CA Sartorius","year":"1994","unstructured":"Sartorius CA, Melville MY, Hovland AR, Tung L, Takimoto GS, Horwitz KB (1994) A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol 8:1347\u20131360","journal-title":"Mol Endocrinol"},{"key":"24_CR180","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1021\/jf047897u","volume":"53","author":"O Schaefer","year":"2005","unstructured":"Schaefer O, Bohlmann R, Schleuning WD, Schulze-Forster K, Humpel M (2005) Development of a radioimmunoassay for the quantitative determination of 8-prenylnaringenin in biological matrices. J Agric Food Chem 53:2881\u20132889","journal-title":"J Agric Food Chem"},{"issue":"Suppl 2","key":"24_CR181","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1464-410X.2007.06942.x","volume":"100","author":"AV Schally","year":"2007","unstructured":"Schally AV (2007) Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art. BJU Int 100(Suppl 2):2\u20134","journal-title":"BJU Int"},{"key":"24_CR182","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","volume":"375","author":"HI Scher","year":"2010","unstructured":"Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J et al (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375:1437\u20131446","journal-title":"Lancet"},{"key":"24_CR183","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1093\/carcin\/bgr188","volume":"32","author":"B Schleipen","year":"2011","unstructured":"Schleipen B, Hertrampf T, Fritzemeier KH, Kluxen FM, Lorenz A, Molzberger A, Velders M, Diel P (2011) ERbeta-specific agonists and genistein inhibit proliferation and induce apoptosis in the large and small intestine. Carcinogenesis 32:1675\u20131683","journal-title":"Carcinogenesis"},{"key":"24_CR184","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1517\/13543770903312946","volume":"19","author":"N Schmees","year":"2009","unstructured":"Schmees N, Weinmann H (2009) Recent patent trends in the field of progesterone receptor agonists and modulators. Expert Opin Ther Pat 19:1521\u20131534","journal-title":"Expert Opin Ther Pat"},{"key":"24_CR185","doi-asserted-by":"publisher","first-page":"17054","DOI":"10.1074\/jbc.M109.099002","volume":"285","author":"A Schmidt","year":"2010","unstructured":"Schmidt A, Kimmel DB, Bai C, Scafonas A, Rutledge S, Vogel RL, McElwee-Witmer S, Chen F, Nantermet PV, Kasparcova V et al (2010) Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem 285:17054\u201317064","journal-title":"J Biol Chem"},{"key":"24_CR186","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0889-8545(02)00052-9","volume":"30","author":"E Seli","year":"2003","unstructured":"Seli E, Berkkanoglu M, Arici A (2003) Pathogenesis of endometriosis. Obstet Gynecol Clin North Am 30:41\u201361","journal-title":"Obstet Gynecol Clin North Am"},{"key":"24_CR187","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2174\/187152009789735044","volume":"9","author":"N Sharifi","year":"2009","unstructured":"Sharifi N (2009) Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function. Anticancer Agents Med Chem 9:1046\u20131051","journal-title":"Anticancer Agents Med Chem"},{"key":"24_CR188","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ucl.2011.09.007","volume":"39","author":"JB Shelton","year":"2012","unstructured":"Shelton JB, Rajfer J (2012) Androgen deficiency in aging and metabolically challenged men. Urol Clin North Am 39:63\u201375","journal-title":"Urol Clin North Am"},{"key":"24_CR189","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S0092-8674(00)81717-1","volume":"95","author":"AK Shiau","year":"1998","unstructured":"Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL (1998) The structural basis of estrogen receptor\/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927\u2013937","journal-title":"Cell"},{"key":"24_CR190","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/AOG.0b013e3181d41191","volume":"115","author":"JL Shifren","year":"2010","unstructured":"Shifren JL, Schiff I (2010) Role of hormone therapy in the management of menopause. Obstet Gynecol 115:839\u2013855","journal-title":"Obstet Gynecol"},{"key":"24_CR191","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/253271a0","volume":"253","author":"RG Smith","year":"1975","unstructured":"Smith RG, Iramain CA, Buttram VC Jr, O'Malley BW (1975) Purification of human uterine progesterone receptor. Nature 253:271\u2013272","journal-title":"Nature"},{"key":"24_CR192","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/GCO.0b013e32832e07e8","volume":"21","author":"IM Spitz","year":"2009","unstructured":"Spitz IM (2009) Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol 21:318\u2013324","journal-title":"Curr Opin Obstet Gynecol"},{"key":"24_CR193","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.contraception.2009.12.012","volume":"82","author":"IM Spitz","year":"2010","unstructured":"Spitz IM (2010) Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception 82:442\u2013452","journal-title":"Contraception"},{"key":"24_CR194","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0079-6123(08)81009-6","volume":"181","author":"V Stanisic","year":"2010","unstructured":"Stanisic V, Lonard DM, O'Malley BW (2010) Modulation of steroid hormone receptor activity. Prog Brain Res 181:153\u2013176","journal-title":"Prog Brain Res"},{"key":"24_CR195","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1097\/01.AOG.0000127622.63269.8b","volume":"103","author":"J Steinauer","year":"2004","unstructured":"Steinauer J, Pritts EA, Jackson R, Jacoby AF (2004) Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 103:1331\u20131336","journal-title":"Obstet Gynecol"},{"key":"24_CR196","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1158\/0008-5472.CAN-08-3605","volume":"69","author":"MP Steinkamp","year":"2009","unstructured":"Steinkamp MP, O'Mahony OA, Brogley M, Rehman H, Lapensee EW, Dhanasekaran S, Hofer MD, Kuefer R, Chinnaiyan A, Rubin MA et al (2009) Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 69:4434\u20134442","journal-title":"Cancer Res"},{"key":"24_CR197","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0002-9378(16)32540-6","volume":"142","author":"RJ Stillman","year":"1982","unstructured":"Stillman RJ (1982) In utero exposure to diethylstilbestrol: adverse effects on the reproductive tract and reproductive performance and male and female offspring. Am J Obstet Gynecol 142:905\u2013921","journal-title":"Am J Obstet Gynecol"},{"key":"24_CR198","first-page":"464","volume":"11","author":"DW Stovall","year":"2010","unstructured":"Stovall DW (2010) Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms. Curr Opin Investig Drugs 11:464\u2013471","journal-title":"Curr Opin Investig Drugs"},{"key":"24_CR199","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2165\/11592820-000000000-00000","volume":"71","author":"DW Stovall","year":"2011","unstructured":"Stovall DW, Tanner-Kurtz K, Pinkerton JV (2011) Tissue-selective estrogen complex bazedoxifene and conjugated estrogens for the treatment of menopausal vasomotor symptoms. Drugs 71:1649\u20131657","journal-title":"Drugs"},{"key":"24_CR200","doi-asserted-by":"publisher","first-page":"7596","DOI":"10.1021\/jm061101w","volume":"49","author":"C Sun","year":"2006","unstructured":"Sun C, Robl JA, Wang TC, Huang Y, Kuhns JE, Lupisella JA, Beehler BC, Golla R, Sleph PG, Seethala R et al (2006) Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold. J Med Chem 49:7596\u20137599","journal-title":"J Med Chem"},{"key":"24_CR201","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0960-0760(03)00197-3","volume":"85","author":"GS Takimoto","year":"2003","unstructured":"Takimoto GS, Tung L, Abdel-Hafiz H, Abel MG, Sartorius CA, Richer JK, Jacobsen BM, Bain DL, Horwitz KB (2003) Functional properties of the N-terminal region of progesterone receptors and their mechanistic relationship to structure. J Steroid Biochem Mol Biol 85:209\u2013219","journal-title":"J Steroid Biochem Mol Biol"},{"key":"24_CR202","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502\u20131512","journal-title":"N Engl J Med"},{"key":"24_CR203","doi-asserted-by":"crossref","unstructured":"Thevis M, Schanzer W (2010) Synthetic anabolic agents: steroids and nonsteroidal selective androgen receptor modulators. Handb Exp Pharmacol, 99\u2013126","DOI":"10.1007\/978-3-540-79088-4_5"},{"key":"24_CR204","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/dta.211","volume":"2","author":"M Thevis","year":"2010","unstructured":"Thevis M, Gerace E, Thomas A, Beuck S, Geyer H, Schlorer N, Kearbey JD, Dalton JT, Schanzer W (2010) Characterization of in vitro generated metabolites of the selective androgen receptor modulators S-22 and S-23 and in vivo comparison to post-administration canine urine specimens. Drug Test Anal 2:589\u2013598","journal-title":"Drug Test Anal"},{"key":"24_CR205","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrc3093","volume":"11","author":"C Thomas","year":"2011","unstructured":"Thomas C, Gustafsson JA (2011) The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11:597\u2013608","journal-title":"Nat Rev Cancer"},{"key":"24_CR206","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0303-7207(75)90056-8","volume":"3","author":"DJ Tindall","year":"1975","unstructured":"Tindall DJ, Hansson V, McLean WS, Ritzen EM, Nayfeh SN, French FS (1975) Androgen-binding proteins in rat epididymis: properties of a cytoplasmic receptor for androgen similar to the androgen receptor in ventral prostate and different from androgen-binding protein (ABP). Mol Cell Endocrinol 3:83\u2013101","journal-title":"Mol Cell Endocrinol"},{"key":"24_CR207","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.amjmed.2010.12.027","volume":"124","author":"AM Traish","year":"2011","unstructured":"Traish AM, Miner MM, Morgentaler A, Zitzmann M (2011) Testosterone deficiency. Am J Med 124:578\u2013587","journal-title":"Am J Med"},{"key":"24_CR208","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787\u2013790","journal-title":"Science"},{"key":"24_CR209","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1210\/jc.2011-0143","volume":"96","author":"TG Travison","year":"2011","unstructured":"Travison TG, Nguyen AH, Naganathan V, Stanaway FF, Blyth FM, Cumming RG, Le Couteur DG, Sambrook PN, Handelsman DJ (2011) Changes in reproductive hormone concentrations predict the prevalence and progression of the frailty syndrome in older men: the concord health and ageing in men project. J Clin Endocrinol Metab 96:2464\u20132474","journal-title":"J Clin Endocrinol Metab"},{"key":"24_CR210","doi-asserted-by":"crossref","first-page":"e009","DOI":"10.1621\/nrs.05009","volume":"5","author":"AM Tremblay","year":"2007","unstructured":"Tremblay AM, Giguere V (2007) The NR3B subgroup: an ovERRview. Nucl Recept Signal 5:e009","journal-title":"Nucl Recept Signal"},{"key":"24_CR211","doi-asserted-by":"publisher","first-page":"39843","DOI":"10.1074\/jbc.M106843200","volume":"276","author":"L Tung","year":"2001","unstructured":"Tung L, Shen T, Abel MG, Powell RL, Takimoto GS, Sartorius CA, Horwitz KB (2001) Mapping the unique activation function 3 in the progesterone B-receptor upstream segment. Two LXXLL motifs and a tryptophan residue are required for activity. J Biol Chem 276:39843\u201339851","journal-title":"J Biol Chem"},{"key":"24_CR212","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1210\/er.2005-0020","volume":"27","author":"JL Turgeon","year":"2006","unstructured":"Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM (2006) Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: insights from basic science and clinical studies. Endocr Rev 27:575\u2013605","journal-title":"Endocr Rev"},{"key":"24_CR213","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.bpobgyn.2004.01.007","volume":"18","author":"P Vigano","year":"2004","unstructured":"Vigano P, Parazzini F, Somigliana E, Vercellini P (2004) Endometriosis: epidemiology and aetiological factors. Best Pract Res Clin Obstet Gynaecol 18:177\u2013200","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"24_CR214","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S1470-2045(10)70021-8","volume":"11","author":"A Vigano","year":"2010","unstructured":"Vigano A, Piccioni M, Trutschnigg B, Hornby L, Chaudhury P, Kilgour R (2010) Male hypogonadism associated with advanced cancer: a systematic review. Lancet Oncol 11:679\u2013684","journal-title":"Lancet Oncol"},{"key":"24_CR215","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/ng0495-401","volume":"9","author":"T Visakorpi","year":"1995","unstructured":"Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401\u2013406","journal-title":"Nat Genet"},{"key":"24_CR216","doi-asserted-by":"publisher","first-page":"8141","DOI":"10.1158\/0008-5472.CAN-09-0919","volume":"69","author":"KK Waltering","year":"2009","unstructured":"Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Janne OA, Visakorpi T (2009) Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69:8141\u20138149","journal-title":"Cancer Res"},{"key":"24_CR217","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1016\/j.bmcl.2009.06.081","volume":"19","author":"DG Washburn","year":"2009","unstructured":"Washburn DG, Hoang TH, Frazee JS, Johnson L, Hammond M, Manns S, Madauss KP, Williams SP, Duraiswami C, Tran TB et al (2009) Discovery of orally active, pyrrolidinone-based progesterone receptor partial agonists. Bioorg Med Chem Lett 19:4664\u20134668","journal-title":"Bioorg Med Chem Lett"},{"key":"24_CR218","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1345\/aph.1Q216","volume":"45","author":"KL Whalen","year":"2011","unstructured":"Whalen KL, Rose R (2011) Estradiol valerate\/dienogest: a novel oral contraceptive. Ann Pharmacother 45:1256\u20131261","journal-title":"Ann Pharmacother"},{"key":"24_CR219","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0022-4731(87)90159-2","volume":"27","author":"R Wiechert","year":"1987","unstructured":"Wiechert R, Neef G (1987) Synthesis of antiprogestational steroids. J Steroid Biochem 27:851\u2013858","journal-title":"J Steroid Biochem"},{"key":"24_CR220","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1152\/advan.00086.2006","volume":"31","author":"ME Wierman","year":"2007","unstructured":"Wierman ME (2007) Sex steroid effects at target tissues: mechanisms of action. Adv Physiol Educ 31:26\u201333","journal-title":"Adv Physiol Educ"},{"key":"24_CR221","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/00006250-199404000-00011","volume":"83","author":"LS Wilcox","year":"1994","unstructured":"Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB (1994) Hysterectomy in the United States, 1988\u20131990. Obstet Gynecol 83:549\u2013555","journal-title":"Obstet Gynecol"},{"key":"24_CR222","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1210\/jc.2008-1104","volume":"93","author":"J Wilkens","year":"2008","unstructured":"Wilkens J, Chwalisz K, Han C, Walker J, Cameron IT, Ingamells S, Lawrence AC, Lumsden MA, Hapangama D, Williams AR, Critchley HO (2008) Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 93:4664\u20134671","journal-title":"J Clin Endocrinol Metab"},{"key":"24_CR223","first-page":"145","volume":"79","author":"JD Wilson","year":"1983","unstructured":"Wilson JD (1983) The endocrine control of sexual differentiation. Harvey Lect 79:145\u2013172","journal-title":"Harvey Lect"},{"key":"24_CR224","first-page":"46","volume":"2","author":"C Wilson","year":"2011","unstructured":"Wilson C (2011) Uterine fibroids: clinical and surgical management. Adv NPs PAs 2:46","journal-title":"Adv NPs PAs"},{"issue":"2","key":"24_CR225","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.neuron.2006.07.023","volume":"52","author":"TM Wintermantel","year":"2006","unstructured":"Wintermantel TM, Campbell RE, Porteous R, Bock D, Gr\u00f6ne HJ, Todman MG, Korach KS, Greiner E, P\u00e9rez CA, Sch\u00fctz G, Herbison AE (2006) Definition of estrogen receptor pathway critical for estrogen positive feedback to gonadotropin-releasing hormone neurons and fertility. Neuron 52(2):271\u201380","journal-title":"Neuron"},{"key":"24_CR226","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000139877","volume":"41","author":"MP Wirth","year":"2008","unstructured":"Wirth MP, Hakenberg OW, Froehner M (2008) Adjuvant hormonal treatment \u2013 the bicalutamide early prostate cancer program. Front Radiat Ther Oncol 41:39\u201348","journal-title":"Front Radiat Ther Oncol"},{"key":"24_CR227","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nsb0196-87","volume":"3","author":"JM Wurtz","year":"1996","unstructured":"Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D, Gronemeyer H (1996) A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol 3:206","journal-title":"Nat Struct Biol"},{"key":"24_CR228","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cger.2010.08.009","volume":"27","author":"QL Xue","year":"2011","unstructured":"Xue QL (2011) The frailty syndrome: definition and natural history. Clin Geriatr Med 27:1\u201315","journal-title":"Clin Geriatr Med"},{"key":"24_CR229","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.bcp.2011.08.006","volume":"82","author":"MR Yudt","year":"2011","unstructured":"Yudt MR, Russo LA, Berrodin TJ, Jelinsky SA, Ellis D, Cohen JC, Cooch N, Haglund E, Unwalla RJ, Fensome A et al (2011) Discovery of a novel mechanism of steroid receptor antagonism: WAY-255348 modulates progesterone receptor cellular localization and promoter interactions. Biochem Pharmacol 82:1709\u20131719","journal-title":"Biochem Pharmacol"},{"key":"24_CR230","doi-asserted-by":"publisher","first-page":"28468","DOI":"10.1074\/jbc.M504144200","volume":"280","author":"Z Zhang","year":"2005","unstructured":"Zhang Z, Olland AM, Zhu Y, Cohen J, Berrodin T, Chippari S, Appavu C, Li S, Wilhem J, Chopra R et al (2005) Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget. J Biol Chem 280:28468\u201328475","journal-title":"J Biol Chem"},{"key":"24_CR231","doi-asserted-by":"crossref","unstructured":"Zhang Z, Lundeen SG, Slayden O, Zhu Y, Cohen J, Berrodin TJ, Bretz J, Chippari S, Wrobel J, Zhang P, et al. (2007) In vitro and in vivo characterization of a novel nonsteroidal, species-specific progesterone receptor modulator, PRA-910. Ernst Schering Found Symp Proc, 171\u2013197","DOI":"10.1007\/2789_2008_078"},{"key":"24_CR232","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2217\/fon.09.106","volume":"5","author":"MF Zilbermint","year":"2009","unstructured":"Zilbermint MF, Dobs AS (2009) Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia. Future Oncol 5:1211\u20131220","journal-title":"Future Oncol"}],"container-title":["Handbook of Experimental Pharmacology","Sex and Gender Differences in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-30726-3_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T04:38:20Z","timestamp":1674189500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-30726-3_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,5]]},"ISBN":["9783642307256","9783642307263"],"references-count":232,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-30726-3_24","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"type":"print","value":"0171-2004"},{"type":"electronic","value":"1865-0325"}],"subject":[],"published":{"date-parts":[[2012,9,5]]},"assertion":[{"value":"5 September 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}